Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations

Previous studies provided conflicting results regarding the association of serum IGF-I or IGF-binding protein-3 (IGFBP-3) and mortality. The aim of this study was to assess the relation of IGF-I and IGFBP-3 levels with mortality from all causes, cardiovascular disease (CVD), and cancer in a prospect...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism Vol. 94; no. 5; p. 1732
Main Authors: Friedrich, Nele, Haring, Robin, Nauck, Matthias, Lüdemann, Jan, Rosskopf, Dieter, Spilcke-Liss, Elisabeth, Felix, Stephan B, Dörr, Marcus, Brabant, Georg, Völzke, Henry, Wallaschofski, Henri
Format: Journal Article
Language:English
Published: United States 01.05.2009
Subjects:
Adult
Aged
Cardiovascular Diseases - genetics
Cardiovascular Diseases - mortality
Female
Follow-Up Studies
Humans
Insulin-Like Growth Factor Binding Protein 3 - blood
Insulin-Like Growth Factor Binding Protein 3 - genetics
Insulin-Like Growth Factor I - genetics
Insulin-Like Growth Factor I - metabolism
Male
Middle Aged
Mortality
Neoplasms - genetics
Neoplasms - mortality
Proportional Hazards Models
Socioeconomic Factors
Young Adult
ISSN:1945-7197, 1945-7197
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous studies provided conflicting results regarding the association of serum IGF-I or IGF-binding protein-3 (IGFBP-3) and mortality. The aim of this study was to assess the relation of IGF-I and IGFBP-3 levels with mortality from all causes, cardiovascular disease (CVD), and cancer in a prospective population-based study. From the Study of Health in Pomerania (SHIP) 1988 men and 2069 women aged 20-79 yr were followed up on average 8.5 yr. Causes of deaths were coded according to the International Classification of Diseases, 10th revision. Serum IGF-I and IGFBP-3 levels were determined by chemiluminescence immunoassays and categorized into three groups (low, normal, high) according to the sex- and age-specific 10th and 90th percentiles. Adjusted analyses revealed that men with low but not high IGF-I levels had an almost 2-fold higher risk of all-cause mortality [hazard ratio (HR) 1.92 (95% confidence interval [CI] 1.35; 2.73)], CVD mortality [HR 1.92 (95% CI 1.00; 3.71)], and cancer mortality [HR 1.85 (95% CI 1.00; 3.45)] compared with men with normal IGF-I levels. In women, no association between IGF-I and mortality was found. Moreover, low IGFBP-3 levels were associated with higher all-cause mortality in men [HR 1.87 (95% CI 1.31; 2.64)] and women [HR 1.63 (95% CI 0.96; 2.76)]. The present study found inverse associations between IGF-I or IGFBP-3 levels and mortality from all causes, CVD, or cancer in men and between IGFBP-3 and all-cause mortality in women.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1945-7197
1945-7197
DOI:10.1210/jc.2008-2138